Pipeline

We are building a robust pipeline of transformative medicines addressing cancer, inflammatory and autoimmune diseases, and fibrosis.

Using our Deep Biology platform, we are advancing multiple large molecule therapeutic candidates with the potential to be first-in-class therapeutics. Our most advanced product candidates are outlined in the chart below:

Immunology

Program

Target ID & Validation

Hit-to-Lead

Lead Optimization

TRB-051*

Lead Optimization

TRB-031*

Lead Optimization

TRB-041*

Hit-to-Lead

TRB-052*

Hit-to-Lead

TRB-061

Hit-to-Lead

TRB-000

Target ID & Validation

*In collaboration with Eli Lilly

Oncology

Program

Target ID & Validation

Hit-to-Lead

Lead Optimization

TRB-012

Lead Optimization

Immunology

Oncology

*Partnered with Eli Lilly.

Discovery Pipeline

In addition to these therapeutic programs, we are developing a broad research pipeline by applying our Deep Biology Platform, identifying novel insights into tissue immune-regulation to drive target identification.

Our Collaborations

We have established a number of collaborations and partnerships with leading industry and academic institutions. Notably, we work with Eli Lilly across 4 programs that have been identified and characterized leveraging TRex’s Deep Biology platform : TRB-031, TRB-041, TRB-051 and TRB-052. In December 2021 we entered into a collaboration with Janssen Pharmaceutica NV for novel targets in Immunology & Inflammation.

Partnered with Lilly